Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1978 1
1984 1
1986 1
1992 1
1993 3
1994 1
1996 3
1997 1
1998 1
1999 3
2000 3
2001 1
2002 4
2003 1
2004 1
2005 1
2006 4
2007 3
2009 2
2010 3
2011 4
2012 3
2013 1
2014 2
2015 1
2016 1
2018 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Anti-DNA antibodies--structure and function.
Rahman A, Kumar S, Potter KN. Rahman A, et al. Among authors: potter kn. Lupus. 2002;11(12):776-9. doi: 10.1191/0961203302lu315oa. Lupus. 2002. PMID: 12529038 Review.
The molecular specificity of insulin autoantibodies.
Potter KN, Wilkin TJ. Potter KN, et al. Diabetes Metab Res Rev. 2000 Sep-Oct;16(5):338-53. doi: 10.1002/1520-7560(2000)9999:9999<::aid-dmrr145>3.0.co;2-l. Diabetes Metab Res Rev. 2000. PMID: 11025558 Review.
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
Chiodin G, Drennan S, Martino EA, Ondrisova L, Henderson I, Del Rio L, Tracy I, D'Avola A, Parker H, Bonfiglio S, Scarfò L, Sutton LA, Strefford JC, Forster J, Brake O, Potter KN, Sale B, Lanham S, Mraz M, Ghia P, Stevenson FK, Forconi F. Chiodin G, et al. Among authors: potter kn. Blood Adv. 2022 Sep 27;6(18):5494-5504. doi: 10.1182/bloodadvances.2021006659. Blood Adv. 2022. PMID: 35640238 Free PMC article.
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trněný M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Strefford JC, et al. Among authors: potter kn. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985. Blood Adv. 2021. PMID: 34323957 Free PMC article.
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.
Nowicka M, Hilton LK, Ashton-Key M, Hargreaves CE, Lee C, Foxall R, Carter MJ, Beers SA, Potter KN, Bolen CR, Klein C, Knapp A, Mir F, Rose-Zerilli M, Burton C, Klapper W, Scott DW, Sehn LH, Vitolo U, Martelli M, Trneny M, Rushton CK, Slack GW, Farinha P, Strefford JC, Oestergaard MZ, Morin RD, Cragg MS. Nowicka M, et al. Among authors: potter kn. Blood Adv. 2021 Aug 10;5(15):2945-2957. doi: 10.1182/bloodadvances.2021004770. Blood Adv. 2021. PMID: 34323958 Free PMC article.
50 results